News

Allon Therapeutics Completes Equity Offering

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC), today announced that it has completed the previously announced public offering of units and common shares resulting in gross proceeds of $4,357,842.50 and a subscription receipt for $1,084,032.50 for a total of $5,441,875 as more particularly ... Continue reading →

Allon granted important U.S. patent for preclinical compound AL-408

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP (davunetide). The D-isomer of davunetide is known as AL-408 in the company’s pipeline.  This new patent streng... Continue reading →

Allon Therapeutics Amends Terms of Offering and Prices Offering

VANCOUVER, B.C. – Allon Therapeutics Inc. (“Allon Therapeutics” or the “Company”) (TSX – “NPC”) announced today that, further to its press release dated September 14, 2011,  that GMP Securities L.P. (the “Lead Agent”), on behalf of a syndicate of agents, including Canaccord Genuity Corp. (togethe... Continue reading →

Allon Therapeutics Announces Overnight Marketed Equity Offering

VANCOUVER, B.C. – Allon Therapeutics Inc. (“Allon Therapeutics” or the “Company”) (TSX – “NPC”) is pleased to announce that it has filed today a short form preliminary prospectus in respect of an overnight marketed offering of units (the “Offering”), each unit being comprised of one common share ... Continue reading →

Allon's CEO presenting at Rodman and Renshaw Global Conference

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress on Tuesday, September 13 at the Rodman and Renshaw Annual Global Investment Conference in New York City. McCauley’s presentation will include an update... Continue reading →

← Older posts Newer posts →